Rajshekar Chakraborty, MD

Hematology/Oncology, Medical Oncology
Accepting New Patients
Virtual Visits/Telehealth
Profile Headshot

Overview

Rajshekhar Chakraborty, MD is an assistant professor of medicine at Columbia University Irving Medical Center in the division of hematology/oncology. After receiving his medical degree from University of Delhi, India, he completed his residency in internal medicine at Icahn School of Medicine at Mount Sinai-Queens Hospital Center. Subsequently, he spent three years as a clinical researcher in plasma cell disorders at the Mayo Clinic, Rochester, followed by fellowship in hematology/oncology at the Cleveland Clinic.

Dr. Chakraborty cares primarily for patients with plasma cells disorders, including multiple myeloma, amyloidosis, MGUS, POEMS syndrome, and Waldenstrom’s macroglobulinemia. His research interests include clinical trials and outcomes research in plasma cell disorders.

Academic Appointments

  • Assistant Professor of Medicine at CUMC

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Gender

  • Male

Schedule an Appointment

Virtual Visits/Telehealth

Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.

Schedule Virtual Visit

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Location(s)

161 Fort Washington Avenue
New York, NY 10032

Insurance Accepted

Aetna

  • Aetna Signature Administrators
  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Student Health

Affinity Health Plan

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs

Amida Care

  • Special Needs

Cigna

  • EPO
  • Great West (National)
  • HMO
  • Medicare Managed Care
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross/Blue Shield

  • EPO
  • HMO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare (National)

  • MagnaCare

Medicare

  • Railroad
  • Traditional Medicare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

Quality Health Management

  • Quality Health Management

RiverSpring

  • Special Needs

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • Empire Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

World Trade Center Health Plan

  • World Trade Center Health Plan

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Research

Selected Publications

  1. Ball S, Behera TR, Anwer F, Chakraborty R. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials. Annals of Hematology. 2020 May 7 [Epub ahead of print]. PMID: 32382772
  1. Chakraborty R, Rybicki L, Nakashima MO, Dean RM, Faiman BM, Samaras CJ, Rosko N, Dysert H, Valent J, Anwer F. Characterization and prognostic impact of immunoparesis in relapsed multiple myeloma. British Journal of Haematology. 2020 Feb 28 [Epub ahead of print]. PMID: 3201832

  1. Chakraborty R, Bin Riaz I, Malik SU, Marneni S, Mejia Garcia A, Anwer F, Khorana AA, Rajkumar SV, Kumar S, Murad MH, Wang Z, Khan SU, Majhail NS. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. Cancer. 2020 Jan 8 [Epub ahead of print]. PMID: 31913498

  1. Chakraborty R, Majhail NS, Anwer F. Denosumab versus zoledronic acid for bone-targeted therapy in multiple myeloma: what are the unanswered questions? JAMA Oncology 2019 Jun 27 [Epub ahead of print]. PMID: 31246229

  1. Chakraborty R, Liu HD, Rybicki L, Tomer J, Khouri J, Dean RM, Faiman BM, Kalaycio M, Samaras BJ, Majhail NS, Valent J. Progression with clinical features is associated with worse subsequent survival in multiple myeloma. American Journal of Hematology. 2019 Apr;94(4):439-445. PMID: 30663805
  1. Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves WI, Gertz MA. Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. British Journal of Haematology. 2018 Jul;182(1):71-77. PMID: 29707759

  1. Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves W, Gertz MA. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia. 2018 Mar;32(3):712-718. PMID: 28848227
  1. Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Serial measurements of circulating plasma cells before and after induction therapy has an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. Haematologica. 2017 Aug;102(8):1439-1445. PMID: 28473618
  1. Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Impact of post-transplant response and minimal residual disease on survival in myeloma with high-risk cytogenetics. Biology of Blood and Marrow Transplantation. 2017 Apr;23(4):598-605. PMID: 28115277

  1. Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. Leukemia & Lymphoma. 2017 Feb;58(2):308-315. PMID: 27390076
  1. Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. The impact of induction regimen choice on transplant outcome and survival in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplantation. 2017 Jan;52(1):34-40. PMID: 27548464
  1. Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer Journal. 2016 Dec 16;6(12):e512. PMID: 27983726
  1. Chakraborty R, Novak AJ, Ansell SM, Muchtar E, Kapoor P, Hayman SR, Dispenzieri A, Buadi FK, Lacy MQ, King RL, Gertz MA. First report of MYD88L265P somatic mutation in IgM-associated light chain amyloidosis. Blood. 2016 Jun 9;127(23):2936-8. PMID: 27034430